Abstract

Organs-on-Chips: Still a Distant Promise or Already a Game Changer?

Sébastien Clerc, Market & Technology Analyst, Yole Développement

Bringing a new drug to market is one of the longest and most costly paths any industry has to walk. The pharmaceutical industry therefore needs more predictive tools to make drug candidates fail earlier and cheaper. Other industries where toxicity testing is a major concern, such as cosmetics, agro-food and consumer goods, also need such solutions, in particular because animal testing is now banned for these industries in certain geographical areas. Organs-on-chips are serious candidates to help solving these bottlenecks.  But despite improving models, the promises that made industrial players dream are now shaded by some skeptic voices. What is the current penetration rate of the technology, does it truly satisfy the industry, and what are the remaining challenges? In this talk, Sébastien Clerc will share Yole’s vision of the organ-on-chip market and technology trends.